Regnum Corp
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C"C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Regnum Corp (RGMP) - Total Liabilities
Latest total liabilities as of March 2023: $1.85 Million USD
Based on the latest financial reports, Regnum Corp (RGMP) has total liabilities worth $1.85 Million USD as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Regnum Corp - Total Liabilities Trend (2016–2022)
This chart illustrates how Regnum Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Regnum Corp Competitors by Total Liabilities
The table below lists competitors of Regnum Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
US Solar Fund PLC
LSE:USFP
|
UK | GBX1.46 Million |
|
VioQuest Pharmaceuticals Inc
PINK:VOQP
|
USA | $6.85 Million |
|
Manila Bulletin Publishing Corp
PSE:MB
|
Philippines | ₱1.91 Billion |
|
Hai Jia International Limited Company
PINK:HBIE
|
USA | $215.00 |
Liability Composition Analysis (2016–2022)
This chart breaks down Regnum Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regnum Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regnum Corp (2016–2022)
The table below shows the annual total liabilities of Regnum Corp from 2016 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $2.03 Million | +8.38% |
| 2021-12-31 | $1.87 Million | +3304.34% |
| 2020-12-31 | $54.89K | +6761.62% |
| 2019-12-31 | $800.00 | -77.99% |
| 2018-12-31 | $3.63K | +66.13% |
| 2017-12-31 | $2.19K | +165.21% |
| 2016-12-31 | $825.00 | -- |